Showing 4861-4870 of 9773 results for "".
- LEO Pharma to Partner with Boehringer Ingelheim, Commercialize SPEVIGO® for GPPhttps://practicaldermatology.com/news/leo-pharma-to-partner-with-boehringer-ingelheim-commercialize-spevigo-for-gpp/2475663/LEO Pharma and Boehringer Ingelheim have entered into an exclusive global license and transfer agreement for the development and commercialization of the interleukin-36 (IL-36) receptor inhibitor SPEVIGO® (spesolimab), according to a news release.
- Study: 90% Would Purchase Red Light Therapy Deviceshttps://practicaldermatology.com/news/study-90-would-purchase-red-light-therapy-devices/2475498/New research published in the Journal of Clinical and Aesthetic Dermatology showed how social media is fueling the growing consumer demand for over-the-counter (OTC) red light therapy (RLT) devices. The authors of the
- Shifting the Perspective: Addressing Social Determinants and Pigmentary Impact in Atopic Dermatitishttps://practicaldermatology.com/news/shifting-the-perspective-addressing-social-determinants-and-pigmentary-impact-in-atopic-dermatitis/2475416/In her presentation “Viewing Atopic Dermatitis Through a Different Lens,” Candrice Heath, MD, FAAD, an associate professor of dermatology at Howard University, used atopic dermatitis (AD) as a case study to examine how social determinants of health (SDOH), skin tone diversity, and structural ineq
- New Data for Lebrikizumab and Tildrakizumab Unveiled at ICD 2025https://practicaldermatology.com/news/new-data-for-lebrikizumab-and-tildrakisumab-unveiled-at-icd-2025/2475320/New real-world and clinical data supporting the use of lebrikizumab in atopic dermatitis (AD) and tildrakizumab in psoriasis was recently presented at the XIV International Congress of Dermatology (ICD) in Rome, according to a press release from Almirall.
- Elevated IFN Signatures Seen in Nonlesional Skin of Cutaneous Lupus Erythematosus Patientshttps://practicaldermatology.com/news/elevated-ifn-signatures-seen-in-nonlesional-skin-of-cle-patients/2475210/Patients with systemic lupus erythematosus (SLE) and a history of cutaneous lupus erythematosus (CLE) showed elevated interferon-stimulated gene (ISG) expression in blood and nonlesional skin, according to a new study. The si
- Midmark Announces First USAB Compliant Procedure Chairhttps://practicaldermatology.com/news/Midmark-Announces-First-USAB-Compliant-Procedure-Chair/2475173/Midmark Corp. announced the launch of the Midmark 631 procedure chair, which the company said is the first US Access Board (USAB) compliant procedure chair. In 2024, the U.S. Access Board issued a new standard establishing design criteria for examination and procedure chairs, as well
- Study: Questionable Efficacy for Complementary and Alternative Skin Care Therapieshttps://practicaldermatology.com/news/study-evaluates-efficacy-of-alternative-therapies-in-skin-care/2475123/Complementary and alternative medicines (CAMs) commonly used in dermatology lack high-quality evidence needed to support their efficacy, according to a comprehensive literature review from researchers at Baylor College of Medicine.
- NEMLUVIO Demonstrates Durable Efficacy and Safety in Atopic Dermatitishttps://practicaldermatology.com/news/nemluvio-demonstrates-durable-efficacy-and-safety-in-atopic-dermatitis/2475110/New two-year interim data from the ARCADIA long-term extension study of NEMLUVIO (nemolizumab) showed sustained improvements in skin and itch outcomes. The therapy was approved by the FDA in December 2024 for the treatment of
- Skin Cancer Champions Launches New Sitehttps://practicaldermatology.com/news/Skin-Cancer-Champions-Launches-New-Site/2475125/Skin Cancer Champions announced the launch of a new website, skincancerchampions.org, aimed at making it easier for patients to find what they need, engage with resources, and help more people discover the community. “Our new site is a step forward in making our community more accessible,
- Study: Lotion Shows Efficacy in Treating Hyperkeratotic Plaque Psoriasishttps://practicaldermatology.com/news/hptaz-lotion-shows-efficacy-in-treating-hyperkeratotic-plaque-psoriasis/2475106/HP/TAZ lotion significantly improved hyperkeratotic psoriatic plaques in subgroups, according to recent data from a post hoc analysis of phase 3 trials. The authors of the post hoc analysis pooled data from two eight-week, v